Japanese biotech firm Pharmafoods is targeting textile supply chains with a regenerated cellulose fibre that incorporates eggshell membrane, Ecotextile News reports from Munich.

The move matters because it comes from outside the conventional fibre establishment. Pharmafoods built its business in food and nutrition ingredients, and its entry into materials means a new supplier is courting fabric mills and brands at a time when sourcing teams are actively screening next-generation fibres (man-made cellulosics, or MMCFs — fibres spun from dissolved plant polymer, like viscose and lyocell).

What is the material actually built on?

The fibre is a regenerated cellulose — cellulose dissolved and re-spun into filament — with eggshell membrane integrated into the polymer. Eggshell membrane is the protein-rich film between an eggshell and its contents, and Pharmafoods has worked with it as a functional ingredient in its core nutrition business. The textile play effectively ports that biomaterial into a cellulosic carrier.

For material developers, that puts the product in the same competitive bracket as other functionalised MMCFs, where additive claims — moisture management, skin-contact benefits — have to be validated through standard testing rather than marketing language.

Where does the story sit in the supply chain?

This is a tier-3 to tier-2 development: fibre production feeding yarn spinners and fabric mills, not a finished-goods story. Brands evaluating it will be doing so at the raw-material R&D stage, comparing it against incumbent cellulosics from established producers.

The commercial fact is the market entry itself. A Japanese biotech with an existing industrial ingredient business is spending development capacity on textiles, which signals it sees sellable volume in the sector — not just a lab demonstration. The announcement came via the Munich-stage reporting of Ecotextile News, the trade outlet that broke the story.

What should compliance teams ask first?

Any sustainability or performance claim attached to the fibre needs tracing back to a standard. Questions sourcing desks will want answered before trial orders:

• Which cellulose feedstock and dissolution process does it use, and is certification available?
• What testing supports the functional claims for the eggshell membrane component?
• Is there confirmed production capacity, or is this a pilot-stage offer?

At this stage, no buyer commitments or order volumes have been reported. Treat the fibre as a development-stage supplier entry, not a proven sourcing option.

The decision it forces

If you run material innovation or MMCF sourcing, Pharmafoods has just added itself to your evaluation list — the move from ingredient biotech into regenerated cellulose is rare enough to warrant an early supplier assessment, well before volumes or certifications are on the table.